SAB Biotherapeutics, Inc.
SABS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.
Other share classesSABSW
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +11 vs. previous quarter
- 87
- 13F valueReported value at the end of Q2 2026
- $266.8M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding SABS, Q2 2026
No superinvestor reported holding SABS at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by SAB Biotherapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 8, 2023 (view filing) | Dec 7 | 1 day | Sullivan Eddie JoeChief Executive Officer | PPurchase | +1.74K | $0.88 | +$1.53K | 0.0%5.23M after | |
| Nov 30, 2023 (view filing) | Nov 30 | Same day | King MichaelCHIEF FINANCIAL OFFICER | PPurchase | +5.00K | $0.90 | +$4.50K | New position5.00K after | |
| Nov 30, 2023 (view filing) | Nov 29 | 1 day | Reich Samuel JExecutive Chairman | PPurchase | +11.0K | $0.89 | +$9.79K | +5.3%219.0K after | |
| Sep 14, 2022 (view filing) | Sep 13 | 1 day | Hamilton Christine EDirector, 10% Owner | PPurchase | +10.0K | $0.73 | +$7.30K | +0.2%4.99M after | |
| Sep 8, 2022 (view filing) | Sep 7 | 1 day | Sullivan Eddie JoeCHIEF EXECUTIVE OFFICER | PPurchase | +14.0K | $0.74 | +$10.4K | +0.3%5.23M after | |
| Nov 16, 2021 (view filing) | Oct 26 | 21 daysLate | Beyer Russell PChief Financial Officer | SSale | −278 | $7.90 | −$2.20K | −100.0%0 after | |
| Oct 15, 2021 (view filing) | Oct 13 | 2 days | Katz IlanDirector, 10% Owner | PPurchase | +500 | $10.11 | +$5.05K | +50.0%1.50K after | |
| Oct 15, 2021 (view filing) | Oct 14 | 1 day | Reich Samuel JCEO and CFO | PPurchase | +1.00K | $10.11 | +$10.1K | New position1.00K after | |
| Oct 5, 2021 (view filing) | Oct 1 | 4 days | Spragens Jeffrey GDirector | PPurchase | +13.0K | $10.07 | +$130.9K | New position13.0K after | |
| Oct 5, 2021 (view filing) | Oct 1 | 4 days | Katz IlanDirector, 10% Owner | PPurchase | +1.00K | $10.09 | +$10.1K | New position1.00K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in SAB Biotherapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Caligan Partners LP | 7,967,207 | $31.1M | 1.50% | 00.0% | Unchanged |
| Vivo Capital, LLC | 7,299,909 | $28.5M | 2.60% | −4,120,091−36.1% | Reduced |
| Perceptive Advisors LLC | 6,627,501 | $25.8M | 0.40% | +195,758+3.0% | Added |
| Adage Capital Partners GP, L.L.C. | 6,405,553 | $25.0M | 0.04% | +3,000,000+88.1% | Added |
| Ra Capital Management, L.P. | 4,401,500 | $17.2M | 0.15% | 00.0% | Unchanged |
| Balyasny Asset Management LLC | 3,760,439 | $14.7M | 0.03% | 00.0% | Unchanged |
| BlackRock, Inc. | 3,066,016 | $12.0M | 0.00% | +2,764,690+917.5% | Added |
| Vanguard Capital Management LLC | 2,972,929 | $11.6M | 0.00% | +479,192+19.2% | Added |
| Commodore Capital LP | 2,870,000 | $11.2M | 0.67% | −1,531,500−34.8% | Reduced |
| Millennium Management LLC | 2,749,087 | $10.7M | 0.01% | −283,610−9.4% | Reduced |